What Is Neurogenetics? Causes, Disorders, and Treatments

Neurogenetics is the medical science of how your genes build and run your brain and nerves, and what goes wrong when a gene changes.1University of Michigan Department of Human Genetics. Neurogenetics Its reach extends past nerve diseases to behaviour and personality traits.2Arq. Neuro-Psiquiatr. A journey through the history of Neurogenetics For most brain conditions there is no single “disease gene.” Risk usually comes from many small genetic nudges combined with life and environment.3PubMed Central. Progress in the Genetics of Polygenic Brain Disorders: Significant New Challenges for Neurobiology

How Genes Cause Brain and Nerve Disorders

A gene change, usually called a variant, is a difference in the DNA spelling of a gene. Severe single-gene variants are real but tend to be rare, because they often make it harder for people to have children and so are less likely to be passed on.4PubMed Central. Progress in the Genetics of Polygenic Brain Disorders: Significant New Challenges for Neurobiology Many common conditions instead result from many genes working together with non-genetic risk factors.5PubMed Central. Progress in the Genetics of Polygenic Brain Disorders: Significant New Challenges for Neurobiology6PubMed Central. Progress in the Genetics of Polygenic Brain Disorders: Significant New Challenges for Neurobiology

The line between one-gene and many-gene disease is blurring. In epilepsy, both common and rare gene changes add to risk.7PubMed. Monogenic no more: are all epilepsies polygenic? A person’s wider genetic background changes how severe a rare variant turns out, how they respond to treatment, and whether it causes illness at all.8PubMed. Monogenic no more: are all epilepsies polygenic? Cerebral palsy, once blamed mainly on birth events, also has both single-gene and many-gene contributions.9PubMed. Cerebral palsy as a childhood-onset neurological disorder caused by both genetic and environmental factors

Not every gene change is inherited. Some happen after conception, so they are present in only some of a person’s cells.10PubMed. Somatic mosaicism and neurodevelopmental disease That means parents can test negative even when a child’s condition is genetic. Such changes are one cause of brain malformations and can contribute to epilepsy, intellectual disability, and autism.11PubMed. Somatic mosaicism and neurodevelopmental disease They may also help explain why some people develop late-life brain diseases that don’t run in the family.12PubMed. Somatic mutations in neurodegeneration

“Genetic” doesn’t always mean passed down from a parent, and carrying a risk variant doesn’t mean you will certainly get ill. For most brain conditions, genes shift the odds rather than decide the outcome.

A clean family history doesn’t rule out genes either. A new change can appear for the first time in a child. A parent can carry a change without symptoms, because the condition needs two faulty copies or shows up only later in life. Small families, adoption, and relatives who died young can also hide a pattern.

Disorders Caused by a Single Gene

Huntington’s disease is caused by a short DNA stretch, CAG, repeated too many times in the huntingtin gene.13PubMed. Mechanisms of neurodegeneration in Huntington’s disease The faulty protein damages nerve cells in brain areas that control movement and thinking.14PubMed. Mechanisms of neurodegeneration in Huntington’s disease The extra repeats can keep growing inside vulnerable brain cells over a lifetime, which affects how the disease progresses.15PubMed. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities Symptoms usually start in adulthood.16PubMed Central. Huntingtin and the molecular pathogenesis of Huntington’s disease. Fourth in molecular medicine review series

Spinal muscular atrophy (SMA) mostly happens when both copies of the SMN1 gene are missing.17Egyptian Journal of Medical Human Genetics. Spinal muscular atrophy in Venezuela: quantitative analysis of SMN1 and SMN2 genes A near-copy gene, SMN2, partly fills in.18PubMed Central. Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development People with more copies of SMN2 usually have milder SMA, so doctors count SMN2 copies to plan care and treatment.19PubMed Central. Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development

Rett syndrome comes from changes in the MECP2 gene, and fragile X syndrome from a silenced FMR1 gene.20PubMed Central. Rett Syndrome and Fragile X Syndrome: Different Etiology With Common Molecular Dysfunctions Both share autism-like features despite different causes.21PubMed Central. Interregulation between fragile X mental retardation protein and methyl CpG binding protein 2 in the mouse posterior cerebral cortex Many epilepsy syndromes are caused by faulty genes for the ion channels that let nerve cells fire.22PubMed. Channelopathies in epilepsy: an overview of clinical presentations, pathogenic mechanisms, and therapeutic insights

Mitochondrial disorders, defects in cell energy, involve more than 400 genes and hit high-energy organs like the brain, eyes, ears, and muscles hardest.23PubMed Central. Mitochondrial Disorders Typical signs include seizures, stroke-like episodes, hearing loss, and exercise intolerance.24PubMed Central. Mitochondrial Disorders Only a few of these genes sit in mitochondrial DNA, which passes from mothers; most follow ordinary inheritance.25PubMed Central. Mitochondrial Disorders

These conditions are passed down in different ways. Huntington’s is dominant: one affected parent gives each child a 50 percent chance of inheriting the change. SMA usually needs a faulty copy from each parent. Parents who each carry one copy are typically unaffected, so it can seem to come from nowhere. Conditions caused by changes in mitochondrial DNA come through the mother, because children inherit their mitochondria from the egg. A genetic counsellor can draw a family tree, work out which pattern fits your family, and say who might be at risk.

Genes in Common Conditions Like Alzheimer’s and Parkinson’s

A rare change in the TREM2 gene makes Alzheimer’s disease roughly five times more likely.26PubMed Central. TREM2 Variants in Alzheimer’s Disease Changes in the GBA gene are a strong risk factor for Parkinson’s that starts early.27PubMed. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson’s Disease Even so, among people with early-onset Parkinson’s, only about 5 in 100 carried a GBA change and 3 in 100 an LRRK2 change.28PubMed. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson’s Disease In families where Parkinson’s runs strongly, LRRK2 and GBA changes play a larger part.29PubMed. Autosomal dominant Parkinson’s disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil

Many carriers have no disease. Among people carrying LRRK2 or GBA changes but without Parkinson’s, only about 11 in 100 and 3 in 100 showed early dopamine loss on brain scans.30PubMed Central. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI): a cross-sectional study Carriers did score slightly higher on mild movement and body-function symptoms than non-carriers.31PubMed Central. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI): a cross-sectional study

A multiplier applies to a starting chance, so five times a small chance can still be a modest chance. The TREM2 change is rare, so it explains only a small share of Alzheimer’s cases overall. A genetic counsellor can give your own lifetime chance based on your age and family history, which is more useful than the multiplier alone.

Consumer DNA tests don’t fully answer this question. They check a limited set of variants, so a negative result doesn’t rule out risk from other genes. A result worth acting on should be confirmed in a clinical lab.

How Doctors Find a Genetic Cause

Exome sequencing reads the protein-making parts of all your genes at once; your report may call it WES. It found a cause in about 40% of people with varied unexplained neurological conditions.32PubMed Central. Whole exome sequencing in neurogenetic odysseys: An effective, cost- and time-saving diagnostic approach The exome test can shorten years of testing and save money.33PubMed Central. Whole exome sequencing in neurogenetic odysseys: An effective, cost- and time-saving diagnostic approach

When first tests are negative, going broader can still pay off. In children with severe epilepsy and developmental delay, whole-genome testing found a cause in about half of those whose exome test was negative.34PubMed. Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies It found one in about two-thirds of those with a negative gene panel, mostly in genes the panel didn’t cover.35PubMed. Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies

The three main tests differ in how much they cover. A gene panel checks a chosen list of genes linked to a condition, so it is fast and focused but can miss genes not on the list. An exome test covers far more ground in a single test. A genome test reads nearly all of the DNA, including stretches between genes, and can catch larger rearrangements that exome tests may miss. Doctors often start narrow when the picture points to certain genes and widen the search if the first test finds nothing.

For a family, the process starts with a blood or saliva sample, often from parents too. Results can take weeks to months. Sometimes the report describes a “variant of uncertain significance,” which is not a diagnosis. As knowledge grows, such results can be re-classified, so ask for them to be re-checked.

Treatments That Target Genes

An antisense oligonucleotide (ASO) is a short piece of DNA-like material that changes the output of a target gene, for example lowering a harmful protein.36PubMed Central. Antisense Oligonucleotides for the Study and Treatment of ALS Tofersen, an ASO drug for ALS caused by the SOD1 gene, was approved in the US in 2023.37PubMed Central. Antisense Oligonucleotide Therapy for Amyotrophic Lateral Sclerosis (ALS): An Umbrella Review It is injected into spinal fluid to get past the brain’s protective barrier.38PubMed Central. Antisense Oligonucleotide Therapy for Amyotrophic Lateral Sclerosis (ALS): An Umbrella Review It lowered SOD1 protein by about 29 to 40% in its main trial.39PubMed Central. Antisense Oligonucleotide Therapy for Amyotrophic Lateral Sclerosis (ALS): An Umbrella Review ASO drugs targeting other ALS genes are in trials.40PubMed Central. Antisense Oligonucleotides for the Study and Treatment of ALS

Timing matters for SMA. In lab-grown spinal cord tissue, an early ASO that raised SMN levels corrected developmental damage.41PubMed Central. Targeted antisense oligonucleotide treatment rescues developmental alterations in spinal muscular atrophy organoids This suggests earlier treatment may help more.

Gene therapy and CRISPR are further from routine use. The blood-brain barrier blocks most drugs from reaching the brain, so engineered viruses that don’t cause disease can carry genes across it.42PubMed. Crossing the blood-brain barrier with AAV vectors High doses can trigger immune reactions and liver harm, so safer versions are being designed.43PubMed. An engineered adeno-associated virus mediates efficient blood-brain barrier penetration with enhanced neurotropism and reduced hepatotropism CRISPR gene editing has corrected faulty genes and reduced damage in animal models of Alzheimer’s and Parkinson’s.44PubMed Central. CRISPR in Neurodegenerative Diseases Treatment: An Alternative Approach to Current Therapies It still needs better delivery and regulation before routine use in people.45PubMed Central. CRISPR–Cas technologies in neurodegenerative disorders: mechanistic insights, therapeutic potential, and translational challenges

Most of these treatments aim to slow or prevent further damage, not to restore nerve cells already lost. Each is built for a particular gene cause, so a treatment for SOD1 ALS does nothing for ALS from other causes. Whether you qualify usually depends on knowing your exact gene change, a good reason to have genetic testing if you have a suspected inherited condition.

To find a gene-targeted trial, ask your neurologist about registries for your condition. Patient groups also track trials. Eligibility often requires a confirmed genetic diagnosis.

Living With a Genetic Test Result

A predictive test tells a healthy person whether they carry a disease gene, as with Huntington’s.46PubMed. The psychological consequences of predictive testing for Huntington’s disease People told their risk was lower felt less distress over the following year.47PubMed. The psychological consequences of predictive testing for Huntington’s disease Those told their risk was higher did not get worse on average, and a year later felt better than people who got no clear answer.48PubMed. The psychological consequences of predictive testing for Huntington’s disease Still, in one family, a result led to years of anxiety, suicide attempts, money problems, and divorce.49PubMed. Ethical aspects of a predictive test for Huntington’s Disease: A long term perspective

Negative results need support too. People with positive and negative results both found coping hard.50PubMed. Psychological reactions to predictive genetic testing for Huntington’s disease: A qualitative study Those testing negative wanted more follow-up than they got.51PubMed. Psychological reactions to predictive genetic testing for Huntington’s disease: A qualitative study

Some questions are worth settling before the test: who you will tell and when, how results might affect insurance where you live, and whether you want to know if no treatment exists. Bringing a support person to the results visit helps.

Can Medicines Be Matched to Your Genes

Differences in people’s genes can change how they respond to the same drug.52PubMed. Pharmacogenomics in neurology: current state and future steps Neurologists aim to pick drugs and doses that work best with the fewest side effects.53PubMed. Pharmacogenomics in neurology: current state and future steps In epilepsy, genetic background affects treatment response.54PubMed. Monogenic no more: are all epilepsies polygenic?

Before starting a new seizure medicine, ask whether a gene test is recommended for that particular drug. Share any previous genetic results with each new doctor, because they can affect drug choices and are easy to lose track of. Not every drug has a useful gene test yet, so a doctor saying none is needed is often correct.